Early Results of MT-401 (Zedenoleucel) in Post-Transplant MRD+ aml …
2022年11月15日 · Zedenoleucel (also known as MT-401) is a non-genetically modified allogeneic multi-tumor associated antigen (mTAA)-specific T cell therapy with selectivity to multiple tumor …
Zedenoleucel (MT-401) granted orphan drug designation by the …
On July 10, 2023, zedenoleucel (MT-401), a multi-tumor-associated antigen (multiTAA)-specific T-cell product, which was previously covered by the AML Hub, was granted orphan drug …
Results from Ongoing Phase 2 Trial of SL-401 As Consolidation …
2016年12月2日 · Background: SL-401 is a novel targeted therapy directed to the interleukin-3 receptor (CD123), a target overexpressed on acute myeloid leukemia (AML) blasts and AML …
European Medicines Agency Grants Orphan Drug Designation for MT-401 ...
2023年7月10日 · MT-401 is currently being studied in a Phase 2 clinical trial for the treatment of relapsed AML following allogeneic HSCT, and was designed to specifically target four different …
Clinical Trial: NCT04511130 - My Cancer Genome
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. …
AML-109 Preliminary Results of MT-401 in Post-Transplant
The lead-in portion of the ARTEMIS results showed that administration of MT-401 converted MRD+ patients to MRD-indicating that early intervention with MT-401 administration at MRD+ …
Novel T-Cell Therapy MT-401 Under Evaluation in Post-Transplant AML
2021年4月2日 · The multitumor-associated antigen (MultiTAA)-specific T-cell product MT-401 is under investigation as a potential treatment option for patients with acute myeloid leukemia …
FDA lifts partial hold on the phase II trial evaluating MT-401 for ...
On January 5, 2021, the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on a phase II trial (NCT04511130) evaluating MT-401 for patients with acute myeloid leukemia …
AML: Treatment of Relapse after Transplant or Extended …
Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market. The purpose of this study is to evaluate safety and …
Efficacy of MT-401 in Patients With AML Following Stem Cell …
This study is a Phase 2 multicenter study with a Safety Lead-in evaluating safety and efficacy of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. …
- 某些结果已被删除